-
THE INCIDENCE, MORTALITY, AND SURVIVAL OF MALIGNANT CHONDROSARCOMA IN THE UNITED STATES: A SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER) 2000-2023 DATABASE ANALYSIS
Aug 11, 2026, 17:15 PM -
NICHE OR COMMON PRACTICE? TRENDS IN AI-ENABLED PLATFORM USE: A CASE STUDY IN ONCOLOGY SLR PROTOCOLS PUBLISHED IN THE COCHRANE LIBRARY
Aug 11, 2026, 17:15 PM -
PATIENT-REPORTED OUTCOMES AND ECONOMIC BURDEN BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE RISK IN JAPAN: ANALYSIS FROM THE JAPAN NATIONAL HEALTH AND WELLNESS SURVEY
Aug 11, 2026, 17:15 PM -
ANTIBIOTIC USAGE PATTERNS IN CHRONIC KIDNEY DISEASE PATIENTS IN A TERTIARY CARE TEACHING HOSPITAL
Aug 11, 2026, 17:15 PM -
ENSURING CONTINUITY OF ACCESS TO HIGH-COST INNOVATIVE THERAPIES DURING QATAR'S MANDATORY HEALTH INSURANCE TRANSITION: EXPERT STAKEHOLDER PERSPECTIVES
Aug 11, 2026, 17:15 PM -
EVALUATING NON-OS ENDPOINTS IN CHRONIC LYMPHOCYTIC LEUKEMIA TRIALS FOR HEALTH TECHNOLOGY ASSESSMENT
Aug 11, 2026, 17:15 PM -
COMBINED DISCRETE CHOICE AND TIME TRADE-OFF METHODS TO ESTIMATE UTILITIES FOR THE SINO-NASAL OUTCOME TEST (SNOT-22) IN CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
Aug 11, 2026, 17:15 PM -
PREVALENCE OF PAIN INTENSITY AND ITS ASSOCIATION WITH HEALTHCARE SERVICE UTILIZATION AMONG US ADULTS WITH PAIN
Aug 11, 2026, 17:15 PM -
THE SCENARIO ANALYSES YOU FORGOT ARE THE ONES THE EAG RUNS: AN LLM SCENARIO-GENERATION AGENT BENCHMARKED AGAINST OMITTED AND EAG-IMPOSED SCENARIOS IN NICE ONCOLOGY APPRAISALS
Aug 11, 2026, 17:15 PM -
BRIDGING THE GAP: ASSESSING THE PREDICTIVE ACCURACY OF EXPERT ELICITATION FOR LONG-TERM SURVIVAL OUTCOMES IN HAEMATO-ONCOLOGY
Aug 11, 2026, 17:15 PM -
ONE POLICY, MANY RESPONSES: MAPPING EUROPEAN STRATEGIES TO U.S. MOST-FAVOURED-NATION PRICING
Aug 11, 2026, 17:15 PM -
OUT-OF-POCKET COSTS AND FINANCIAL BURDEN OF DUCHENNE MUSCULAR DYSTROPHY IN GREECE: A CROSS-SECTIONAL STUDY
Aug 11, 2026, 17:15 PM -
HEARD BUT NOT SEEN: PATIENT AND CLINICIAN INPUT IN THE FIRST ORPHAN JCA
Aug 11, 2026, 17:15 PM -
IMPACT OF UPDATED REAL-WORLD VACCINE EFFECTIVENESS EVIDENCE ON THE ESTIMATED PUBLIC HEALTH AND ECONOMIC VALUE OF MRNA-1283 VERSUS BNT162B2 IN THE NETHERLANDS
Aug 11, 2026, 17:15 PM -
ESTIMATING THE UK POPULATION ELIGIBLE FOR LATE-LINE MULTIPLE MYELOMA THERAPIES USING AN EPIDEMIOLOGICAL MODEL
Aug 11, 2026, 17:15 PM -
CONSANGUINITY-ADJUSTED BUDGET IMPACT OF ORPHAN DRUG ACCESS FOR HEREDITARY TYROSINEMIA TYPE 1 IN MOROCCO: A PAYER-PERSPECTIVE MODEL
Aug 11, 2026, 17:15 PM -
EFFICACY, SAFETY, AND PATIENT-REPORTED OUTCOMES OF ONCE-WEEKLY SOMAPACITAN AND SOMATROGON IN CHILDREN WITH GROWTH HORMONE DEFICIENCY: A SYSTEMATIC REVIEW
Aug 11, 2026, 17:15 PM -
PRICE NEGOTIATION FOR HIGH-COST THERAPIES: A REVIEW OF THEORIES, STRATEGIES AND FACTORS INFLUENCING BARGAINING POWER
Aug 11, 2026, 17:15 PM -
TIME TO REIMBURSEMENT OF MULTIPLE SCLEROSIS THERAPIES IN POLAND ANALYSIS OF HTA SUBMISSION AND REIMBURSEMENT DECISIONS
Aug 11, 2026, 17:15 PM -
CONVERSION-TO-OPEN SURGERY AVOIDED BY ROBOTIC-ASSISTED SURGERY IN SWEDISH COLORECTAL CANCER: A 10-YEAR NATIONAL-REGISTRY BUDGET-IMPACT ANALYSIS, 2015-2024
Aug 11, 2026, 17:15 PM
